We speculate that this extra-hepatic effect of the HSD17B13 S33A mutation is secondary to hepatic insulin resistance caused by liver steatosis, which reflects a critical role of HSD17B13 in hepatocytes, consistent with the highly selective expression of HSD17B13 in the liver. Here, HSD17B13 is linked to fatty liver disease.